Mersana Therapeutics (MRSN) IPO Opens Modestly Lower
Get Alerts MRSN Hot Sheet
Join SI Premium – FREE
Today's IPO for Mersana Therapeutics (NASDAQ: MRSN) opened for trading at $14.25 after pricing 5,000,000 shares of common stock at a public offering price of $15.00 per share.
J.P. Morgan, Cowen and Leerink Partners acted as book-running managers for the offering. Wedbush PacGrow acted as co-manager for the offering.
Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary ADC platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead product candidate, XMT-1522, is in Phase I clinical trials. We expect that our second product candidate, XMT-1536, will be entering clinical trials in early 2018. In addition, our partners are advancing their pipeline of ADCs using our platform.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reddit (RDDT): Received a Letter From the FTC of Non-public Inquiry into its AI Models
- TD Cowen Reiterates Outperform Rating on FedEx (FDX) Into EPS
- Adobe (ADBE) PT Lowered to $640 at TD Cowen
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Cowen & Co, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!